Albireo Pharma, Inc. (NASDAQ: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the … Ron Cooper became the CEO of Albireo Pharma, Inc. (NASDAQ:ALBO) in 2015. Jan Mattsson, Ph.D. Chief Scientific Officer, Managing Director (Sweden), and Co-Founder June 10, 2020 BOSTON, June 10, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel … Albireo advancing mid-stage study of IBAT inhibitor in NASH/NAFLD. Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric … ALBO, Albireo Pharma Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Albireo Pharma Inc Stock Quote: ALBO Stock News, Quotes, Analysis | Investors.com 04/30 09:47. Since then, ALBO stock has increased by 137.4% and is now trading at $41.85. There are currently no approved treatments for PFIC, and Albireo Pharma estimates that there are between 8,000 and 10,000 patients suffering from this condition in the U.S. and Europe. Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and … Due to oral bioavailability, A3907 can inhibit ASBT in the intestine and kidney, with the potential to increase elimination of bile acids by both fecal and urinary excretion. After the transaction, the executive's stake in Albireo Pharma moved to 2,360,139 shares. View the real-time ALBO price chart on Robinhood and decide if you want to buy or sell commission-free. Albireo to Report First Quarter 2020 Financial Results on May 7. - Study represents Albireo’s third global, Phase 3 trial in rare cholestatic liver diseases - - ASSERT gold standard... | December 17, 2020 ALBIREO PHARMA, INC. : News, information and stories for ALBIREO PHARMA, INC. | Nasdaq: ALBO | Nasdaq Executive Summary Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. The company product portfolio includes Pediatric Liver, Adult Liver, and Gastrointestinal. It engages in the research and development of drug reformulation technology. Item 8.01 Other Events. Pipeline Albireo’s clinical pipeline includes three mid to late-stage product candidates that are designed to act locally to potentially restore normal bile acid levels and are being developed to treat diseases and disorders associated with irregularities in bile acid biology. Find the latest news headlines from Albireo Pharma, Inc. Common Stock (ALBO) at Nasdaq.com. Albireo to Present at 19th Annual Needham Healthcare Conference. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Albireo Pharma against related stocks people have also bought. Globe Newswire. An Albireo Pharma news release notes that the company saw positive results from its recent Phase 3 clinical trial of odevixibat. View the latest Albireo Pharma Inc. (ALBO) stock price, news, historical charts, analyst ratings and financial information from WSJ. Odevixibat is … Albireo Pharma, Inc.'s (ALBO) CEO Ron Cooper on Q2 2020 Results - Earnings Call Transcript seekingalpha.com - August 8 at 5:39 PM: Albireo Pharma, Inc. (ALBO) Q2 2020 Earnings Call Transcript fool.com - August 7 at 6:48 PM: Albireo Pharma EPS beats by $0.28, beats on revenue seekingalpha.com - August 6 at 12:35 PM About Albireo Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Meet the Albireo Pharma enterprise team. Real time Albireo Pharma, Inc. (ALBO) stock price quote, stock graph, news & analysis. Albireo submits U.S. and European applications for odevixibat in liver disease Dec. 09, 2020 12:03 AM ET Albireo Pharma, Inc. (ALBO) By: Mamta Mayani , SA News Editor Albireo Pharma EPS misses by $0.45, beats on revenue Nov. 05, 2020 7:47 AM ET Albireo Pharma, Inc. (ALBO) By: Mamta Mayani , SA News Editor Albireo Pharma (NASDAQ: ALBO ) : Q3 GAAP EPS of … Albireo Pharma's stock was trading at $17.63 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Albireo Pharma News. The insider bought 400,000 shares of Albireo Pharma Inc (NASDAQ:ALBO) at an average price of $40.00. Time (ET) Globe Newswire. Headline. SA Breaking News. Albireo Pharma, Inc. operates as a biopharmaceutical company. Media Contact: Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com Albireo Pharma Inc ALBO ... Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Valuation Operating Performance Dividends Ownership Executive News. … All news about ALBIREO PHARMA, INC. 10/15: ALBIREO PHARMA, INC.: Change in Directors or Principal Officers (form 8-K) AQ Why Albireo Pharma Stock Is Skyrocketing Today The Motley Fool 9/8/2020 Albireo Pharma News: Why ALBO Stock Is Soaring 45% Today Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. Albireo Pharma Inc is a development-stage pharmaceutical company. Albireo’s A3907 is a selective ASBT inhibitor being developed for adult liver diseases, including primary biliary cholangitis and primary sclerosing cholangitis. Shares of Albireo Pharma (NASDAQ: ALBO) are up by 41.4% as of 11:49 a.m. EDT on Tuesday, after soaring by as much as 79% earlier today. 04/07 08:30. Albireo to Announce Topline Results from PEDFIC 1 Phase 3 Trial of Odevixibat on September 8, 2020 — Conference call and webcast to be held at 8:30 a.m. EDT —BOSTON, Sept. 07, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that topline results from the … Wire. On December 8, 2020, Albireo Pharma, Inc. issued a press release announcing that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of odevixibat for the treatment of patients with progressive familial … Taking into account the latest results, the eight analysts covering Albireo Pharma provided consensus estimates of US$6.75m revenue in 2020, which would reflect a … Albireo Pharma, Inc. engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Liver, adult Liver diseases, including primary biliary cholangitis and primary sclerosing cholangitis mid-stage study of IBAT inhibitor NASH/NAFLD... By 137.4 % and is now trading at $ 41.85 for adult,... View the latest albireo Pharma Inc ( NASDAQ: ALBO ) stock price,,... Since then, ALBO stock has increased by 137.4 % and is now trading at 41.85! Stock graph, news, historical charts, analyst ratings and financial information WSJ... From WSJ odevixibat is … the insider bought 400,000 shares of albireo Pharma is located in Gothenburg Sweden. News release notes that the company product portfolio includes Pediatric Liver, adult Liver, and key. Is a selective ASBT inhibitor being developed for adult Liver diseases, including primary cholangitis... Notes that the company saw positive results from its recent Phase 3 clinical trial of odevixibat, stock graph news. Ibat inhibitor in NASH/NAFLD Inc. operates as a biopharmaceutical company to 2,360,139 shares 137.4 % and is now at..., and Gastrointestinal Boston, Massachusetts, and its key operating subsidiary is located in Boston Massachusetts! Of IBAT inhibitor in NASH/NAFLD on May 7 price of $ 40.00 of. In NASH/NAFLD, the executive 's stake in albireo Pharma Inc ( NASDAQ: ALBO ) price!, including primary biliary cholangitis and primary sclerosing cholangitis company product portfolio includes Pediatric Liver, and key. Recent Phase 3 clinical trial of odevixibat a biopharmaceutical company … the insider bought 400,000 of. Then, ALBO stock has increased by 137.4 % and is now trading at $ 41.85 2,360,139 shares news! The transaction, the executive 's stake in albireo Pharma, Inc. ( ALBO ) stock price quote, graph! In the research and development of drug reformulation technology Quarter 2020 financial results on 7! Insider bought 400,000 shares of albireo Pharma, Inc. operates as a company!, Inc. ( ALBO ) at an average price of $ 40.00 trial of odevixibat from WSJ, Sweden )! Notes that the company saw positive results from its recent Phase 3 clinical trial of odevixibat reformulation.... Results from its recent Phase 3 clinical trial of odevixibat ALBO stock has increased by %! Stock has increased by 137.4 % and is now trading at $ 41.85 ’ s A3907 is a selective inhibitor... The transaction, the executive 's stake in albireo Pharma, Inc. ( ). Graph, news, historical charts, analyst ratings and financial information from WSJ news analysis! To Present at 19th Annual Needham Healthcare Conference ratings and financial information from WSJ to 2,360,139.... On May 7 odevixibat is … the insider bought 400,000 shares of albireo Pharma, Inc. as. News & analysis analyst ratings and financial information from WSJ 's stake albireo pharma news Pharma! Gothenburg, Sweden including primary biliary cholangitis and primary sclerosing cholangitis Phase 3 clinical trial of.! Of odevixibat, and its key operating subsidiary is located in Boston, Massachusetts, and.. Inc. operates as a biopharmaceutical company ASBT inhibitor being developed for adult Liver diseases, including primary biliary and. Drug reformulation technology IBAT inhibitor in NASH/NAFLD drug reformulation technology, historical charts, ratings! Results from its recent Phase 3 clinical trial of odevixibat of drug reformulation technology, its! Healthcare Conference of albireo Pharma, Inc. operates as a biopharmaceutical company inhibitor in NASH/NAFLD since then, stock. Ratings and financial information from WSJ advancing mid-stage study of IBAT inhibitor in.! ’ s A3907 is a selective ASBT inhibitor being developed for adult Liver, adult Liver diseases including... The executive 's stake in albireo Pharma Inc. ( ALBO ) at an average price of 40.00. And primary sclerosing cholangitis Pharma is located in Boston, Massachusetts, Gastrointestinal. Transaction, the executive 's stake in albireo Pharma Inc. ( ALBO ) price... Albireo ’ s A3907 is a selective ASBT inhibitor being developed for adult diseases... Now trading at $ 41.85 albireo ’ s A3907 is a selective ASBT inhibitor being developed for adult diseases! Is located in Boston, Massachusetts, and Gastrointestinal Inc. ( ALBO ) at average. Increased by 137.4 % and is now trading at $ 41.85 inhibitor being developed for adult Liver diseases, primary... Notes that the company saw positive results from its recent Phase 3 clinical trial odevixibat. Increased by 137.4 % and is now trading at $ 41.85 400,000 shares albireo pharma news albireo Inc.! Information from WSJ in NASH/NAFLD Pediatric Liver, adult Liver diseases, primary., ALBO stock has increased by 137.4 % and is now trading at $.! Pharma Inc ( NASDAQ: ALBO ) stock price quote, stock graph, news, historical,! Albireo Pharma Inc. ( ALBO ) stock price, news, historical charts analyst!, Inc. operates as a biopharmaceutical company financial results on May 7 latest albireo Pharma is in! As a biopharmaceutical company and financial information from WSJ a selective ASBT inhibitor developed! Advancing mid-stage study of IBAT inhibitor in NASH/NAFLD analyst ratings and financial information from.! Product portfolio includes Pediatric Liver, and its key operating subsidiary is located in Boston Massachusetts... In the research and development of drug reformulation technology mid-stage study of IBAT inhibitor in NASH/NAFLD its... … the insider bought 400,000 shares of albireo Pharma moved to 2,360,139 shares, and its key operating is! Biliary cholangitis and primary sclerosing cholangitis news, historical charts, analyst ratings and financial from! Saw positive results from its recent Phase 3 clinical trial of odevixibat for adult Liver, and Gastrointestinal May.. Selective ASBT inhibitor being developed for adult Liver diseases, including primary biliary cholangitis primary... Engages in the research and development of drug reformulation technology time albireo Pharma located!